Pharma companies win reversal of US fraud pricing verdicts
This article was originally published in Scrip
Executive Summary
The Alabama Supreme Court has overturned two jury verdicts against three pharmaceutical manufacturers awarding the state more than $274 million. The court ruled there was no basis for the state's claims that AstraZeneca, Novartis and GlaxoSmithKline committed fraud by manipulating average wholesale prices (AWP) sent to reporting services, resulting in inflated prices reimbursed by the Alabama Medicaid agency.